Biohaven Ltd. Investment Income, Interest and Dividend
Biohaven Ltd. (BHVN) reported Investment Income, Interest and Dividend of $2.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterestAndDividend · last filed 2026-08-10
- Biohaven Ltd. investment income, interest and dividend for the quarter ending 2026-06-30 was $2.71M, a 35.52% decline year-over-year.
- Biohaven Ltd. investment income, interest and dividend for the quarter ending 2026-03-31 was $3.28M, a 22.72% decline year-over-year.
- Biohaven Ltd. investment income, interest and dividend for the quarter ending 2025-12-31 was $2.83M, a 55.40% decline year-over-year.
- Biohaven Ltd. investment income, interest and dividend for the quarter ending 2025-09-30 was $3.45M, a 39.36% decline year-over-year.
- Biohaven Ltd. investment income, interest and dividend for fiscal 2025 was $14.72M, a 31.57% decline from fiscal 2024.
- Biohaven Ltd. investment income, interest and dividend for fiscal 2024 was $21.51M, a 20.03% increase from fiscal 2023.
- Biohaven Ltd. investment income, interest and dividend for fiscal 2023 was $17.92M, a 454.00% increase from fiscal 2022.
- Biohaven Ltd. investment income, interest and dividend for fiscal 2022 was $3.23M.
| Period end | Investment Income, Interest and Dividend 3 month | Investment Income, Interest and Dividend 3 month as first filed | Investment Income, Interest and Dividend 6 month | Investment Income, Interest and Dividend 6 month as first filed | Investment Income, Interest and Dividend 9 month | Investment Income, Interest and Dividend 9 month as first filed | Investment Income, Interest and Dividend 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.71M 10-Q · filed 2026-08-10 | $5.98M 10-Q · filed 2026-08-10 | $8.81M derived: sum of 3 quarters · filed 2026-08-10 | $12.27M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $3.28M 10-Q · filed 2026-05-04 | $6.11M derived: sum of 2 quarters · filed 2026-05-04 | $9.56M derived: sum of 3 quarters · filed 2026-05-04 | $13.76M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-12-31 | $2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $6.28M derived: sum of 2 quarters · filed 2026-03-02 | $10.48M derived: sum of 3 quarters · filed 2026-08-10 | $14.72M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $3.45M 10-Q · filed 2025-11-10 | $7.65M derived: sum of 2 quarters · filed 2026-08-10 | $11.89M 10-Q · filed 2025-11-10 | $18.24M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $4.20M 10-Q · filed 2026-08-10 | $8.44M 10-Q · filed 2026-08-10 | $14.78M derived: sum of 3 quarters · filed 2026-08-10 | $20.48M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $4.24M 10-Q · filed 2026-05-04 | $10.59M derived: sum of 2 quarters · filed 2026-05-04 | $16.28M derived: sum of 3 quarters · filed 2026-05-04 | $21.42M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.04M derived: sum of 2 quarters · filed 2026-03-02 | $17.18M derived: sum of 3 quarters · filed 2026-03-02 | $21.51M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $5.69M 10-Q · filed 2025-11-10 | $10.83M derived: sum of 2 quarters · filed 2025-11-10 | $15.16M 10-Q · filed 2025-11-10 | $20.89M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-06-30 | $5.14M 10-Q · filed 2025-08-11 | $9.47M 10-Q · filed 2025-08-11 | $15.20M derived: sum of 3 quarters · filed 2026-03-02 | $19.03M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2024-03-31 | $4.33M 10-Q · filed 2025-05-12 | $10.06M derived: sum of 2 quarters · filed 2026-03-02 | $13.89M derived: sum of 3 quarters · filed 2026-03-02 | $18.06M derived: sum of 4 quarters · filed 2026-03-02 | |||
| 2023-12-31 | $5.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.56M derived: sum of 2 quarters · filed 2026-03-02 | $13.73M derived: sum of 3 quarters · filed 2026-03-02 | $17.92M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $3.83M 10-Q · filed 2024-11-12 | $8.00M derived: sum of 2 quarters · filed 2024-11-12 | $12.19M 10-Q · filed 2024-11-12 | $12.23M 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $4.17M 10-Q · filed 2024-08-09 | $4.18M 10-Q · filed 2023-07-31 | $8.36M 10-Q · filed 2024-08-09 | $8.40M 10-Q · filed 2023-07-31 | |||
| 2023-03-31 | $4.17M 10-Q · filed 2024-05-09 | $4.19M 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | $3.23M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |